Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $21.00 Consensus PT from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been assigned a consensus recommendation of “Buy” from the eight research firms that are currently covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $21.00.

A number of research firms have recently weighed in on ZVRA. Roth Mkm upped their price objective on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Guggenheim initiated coverage on Zevra Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $20.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a report on Friday, October 11th. Canaccord Genuity Group cut their price objective on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. Finally, Maxim Group boosted their target price on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th.

Zevra Therapeutics Trading Down 2.0 %

Shares of NASDAQ:ZVRA opened at $8.39 on Friday. Zevra Therapeutics has a 52-week low of $4.20 and a 52-week high of $9.76. The stock has a market capitalization of $447.82 million, a price-to-earnings ratio of -4.26 and a beta of 1.97. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The stock’s 50-day simple moving average is $8.74 and its two-hundred day simple moving average is $7.39.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The company had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter last year, the company earned ($0.40) earnings per share. Analysts expect that Zevra Therapeutics will post -1.96 EPS for the current year.

Hedge Funds Weigh In On Zevra Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in Zevra Therapeutics in the third quarter worth about $127,000. Barclays PLC grew its holdings in Zevra Therapeutics by 292.6% during the third quarter. Barclays PLC now owns 57,599 shares of the company’s stock worth $399,000 after acquiring an additional 42,926 shares during the period. Geode Capital Management LLC grew its stake in shares of Zevra Therapeutics by 14.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock worth $7,246,000 after purchasing an additional 129,600 shares during the period. XTX Topco Ltd purchased a new position in Zevra Therapeutics in the third quarter valued at $94,000. Finally, State Street Corp raised its holdings in Zevra Therapeutics by 7.4% in the 3rd quarter. State Street Corp now owns 772,825 shares of the company’s stock worth $5,363,000 after purchasing an additional 52,966 shares during the period. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.